Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine.
azacitidine
bone marrow histology
myelodysplastic syndromes
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Oct 2021
20 Oct 2021
Historique:
received:
20
09
2021
revised:
11
10
2021
accepted:
18
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
High-risk Myelodysplastic syndromes (MDS) represent therapeutical challenges and are usually managed with hypomethylating agents such as azacitidine. Given the lack of data in the literature concerning azacitidine effects on bone marrow, we retrospectively analyzed 57 high-risk MDS cases in order to identify any changes induced by azacitidine therapy or relevant correlations between therapy response and pre- or post-treatment features. Azacitidine treatment had no significant impact on bone marrow cellularity or morphological dysplastic features. On the contrary, although not statistically significant, we observed a slight decrease in CD34+ and CD117+ blasts and p53+ precursors after treatment. Moreover, pre-treatment IPSS-R cytogenetic score (
Identifiants
pubmed: 34768330
pii: jcm10214809
doi: 10.3390/jcm10214809
pmc: PMC8584458
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
N Engl J Med. 2020 Oct 1;383(14):1358-1374
pubmed: 32997910
Leukemia. 1993 May;7 Suppl 1:21-9
pubmed: 7683352
Blood. 2019 Mar 7;133(10):1020-1030
pubmed: 30404811
Haematologica. 2016 Aug;101(8):e320-3
pubmed: 27081179
Blood. 2011 Jan 13;117(2):403-11
pubmed: 20940414
Cytometry A. 2018 Jul;93(9):916-928
pubmed: 30211968
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Semin Hematol. 2018 Oct;55(4):202-208
pubmed: 30502848
Pathobiology. 2007;74(2):89-96
pubmed: 17587880
Leuk Res. 2002 Jun;26(6):525-30; discussion 531
pubmed: 12007498
Mod Pathol. 2017 Mar;30(3):382-392
pubmed: 27934876
Haematologica. 2019 Aug;104(8):e345-e348
pubmed: 30792212
Cancer Manag Res. 2009 Oct 09;1:119-30
pubmed: 21188130
Leuk Res. 2015 Sep;39(9):957-63
pubmed: 26209197
Blood. 2020 Dec 10;136(24):2812-2823
pubmed: 32730593
Oncotarget. 2016 May 24;7(21):30492-503
pubmed: 27127180
Crit Rev Oncol Hematol. 2016 Nov;107:90-99
pubmed: 27823655
Leuk Res. 2012 Jul;36(7):921-30
pubmed: 22503132
Leukemia. 2015 Jul;29(7):1502-13
pubmed: 25721895
Ann Hematol. 2021 Jul;100(7):1711-1722
pubmed: 33423077
Drugs. 2016 May;76(8):889-900
pubmed: 27193945
Am J Hematol. 2016 Jan;91(1):76-89
pubmed: 26769228
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Leuk Res. 2008 Jul;32(7):1026-35
pubmed: 18006057
Blood. 2019 Feb 7;133(6):521-529
pubmed: 30545832
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Clin Lymphoma Myeloma Leuk. 2020 May;20(5):324-328
pubmed: 32044274